Human Anti-ERBB2 Recombinant Antibody (clone 39S) (CAT#: PABC-447)

Figure 1 The 39S antibody functions synergistically with trastuzumab in inhibiting NCI-N87 cell proliferation in vitro.

Representative graph shows the mean percent growth inhibition ± SEM (n = 3). *I> 0 at all treatment concentrations (at 0.01 type I error level) indicating a strong synergistic effect.

Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., ... & Feng, H. (2016). A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer cell, 29(1), 117-129.

Figure 2 The biparatopic antibody blocks ligand-induced HER2-HER3 receptor dimerization in T47D cells.

Serum-starved T47D cells were incubated for 10 min in the presence (+) or absence (-) of heregulin- 1b (HRG1, 1 nM) and antibody (5 nM in concentration for each antibody) and then lysed. Cell lysates were immunoprecipitated with an HER2-specific antibody and the HER2-HER3 immunocomplex was detected by western blot. Immunoblots show the formation of HER2-HER3 complex in response to the treatment.

Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., ... & Feng, H. (2016). A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer cell, 29(1), 117-129.

Figure 3 HER2 receptor internalization induced by the biparatopic antibody in comparison with the monospecific antibodies and antibody combinations.

Representative graph shows the mean percent internalization ± SEM (n = 3) in BT474 cells. *p < 0.001 by Student's t test compared with trastuzumab.

Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., ... & Feng, H. (2016). A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer cell, 29(1), 117-129.

Figure 4 The biparatopic antibody promotes HER2 clustering and lysosomal degradation.

Representative immunoblots of lysates from antibody (500 nM)-treated BT474 cells showing that the biparatopic antibody induces HER2 degradation.

Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., ... & Feng, H. (2016). A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer cell, 29(1), 117-129.